Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Lower volumes and prices have hit the pharma giant's asthma product sales in the past
Thursday 20 Jul 2017 Author: Lisa-Marie Janes

Wednesday 26 July

Investors should check whether sales of GlaxoSmithKline’s (GSK) asthma treatments have further declined when it reports half year results on 26 July. In April, sales of its Advair/Seretide products in the US fell due to lower volumes and prices.

Generic competition against Advair has been restrained after the US Food and Drug Administration prevented US rival Mylan from launching its Wixela Inhub product in its current form.

‹ Previous2017-07-20Next ›